Hanmi Pharmaceutical said that it has become the first local corporation to launch a three-substance combination drug in Latin America.
|Hanmi headquarters in Bangi-dong, eastern Seoul.|
The company plans to export Amosartan Plus, and Amosartan Q, its dyslipidemia and hypertension treatments, to Silanes, a Mexican pharmaceutical company, and will proceed with full-scale procedures for market approval from next year.
Hanmi Pharmaceutical plans to export $10 million worth of products over five years, while Silanes will apply for licenses for both products in the second half of 2020 and plans to start marketing the drugs by the second quarter of 2021.
Hanmi Pharm received the first milestone from Silanes with the agreement, and will receive additional milestones after the product launch. The two companies agreed not to disclose the amount of the milestone.
Amosartan Plus is the follow-up drug of Amosartan with diuretic compound Chlortalidone. Amosartan is more effective for patients who can’t reduce blood pressure with drugs that have two compounds. Amosartan Q is hypertension and hyperlipidemia complex with three compounds to combine Amosartan and hyperlipidemia compound rosuvastatin.
“The agreement with Silanes will become the cornerstone for expanding the exports of various new drugs developed by Hanmi,” a company official said. “We will do our best to expand the shipment of our products to various countries besides Latin America.”